Medexus Pharmaceuticals Inc. MDP
TSX · Canada · Health Technology
CAD 4.92-0.08 (-1.60%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 10, 2026 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the...
Medexus Pharmaceuticals (TSE:MDP) reported higher first-quarter fiscal 2027 revenue and adjusted EBITDA, supported by continued growth for GRAFAPEX and a stronger contribution from IXINITY, while management maintained its full-year outlook for the recently launched transplant-conditioning product.
Strong quarterly performance driven by record Graphopex sales and strategic expansion into cell therapy.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.